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Summary
Objective: Diacetylrhein or diacerein has shown e$cacy in the treatment of both major forms of osteoarthritis (OA),
coxarthrosis as well as gonarthrosis, improving clinical symptoms of the disease (pain reduction and algo-functional
index). Both in-vitro and animal models studies suggest that diacerein may have also disease-modifying e#ects. The
drug exerts inhibitory e#ects on interleukin-1-induced expression of cartilage degrading enzymes. However, its
mechanism of action is not completely understood. In view of the role that could play the transforming growth factor
(TGF)-â system in the repair potentialities of OA cartilage, we studied the e#ect of diacerein on the expression of TGF-â
isoforms 1, 2 and 3 and that of their receptor types I and II in cultured bovine chondrocytes.
Methods: Cultured bovine articular chondrocytes were treated with 10"5 m diacerein, 10 ng/ml IL-1â or the
combination diacerein+interleukin (IL)-1, and the expression of both TGF-â isoforms 1, 2 and 3 and that of their
receptors TâR-I and TâR-II was determined by Northern-blot and reverse transcriptase-polymerase chain reaction
(RT-PCR). Cell transfections of cDNA constructs containing sequences of the 5*-upstream region of TGF-â1 promoter
were also performed to determine their transcriptional activity in diacerein-treated cultures.
Results: The data indicated that diacerein enhances the expression of TGF-â1 and TGF-â2. This e#ect was also
found in the presence of IL-1, albeit with smaller intensity. In contrast, the levels of TGF-â3 and receptors I and II
remained una#ected or slighty modified by the compound. Treatment of cells transiently transfected with
TGF-â1 promoter constructs suggested that the stimulating e#ect on TGF-â1 expression is mediated by the region
"1038 to "1132 base pars.
Conclusion: The results suggest that diacerein e#ects on matrix synthesis and turn-over previously reported in
cultured articular chondrocytes might be explained in part by the ability of the drug to enhance TGF-â1 and TGF-â2
expression in these cells. This mechanism of action may account for the potential disease-modifying properties of
diacerein and might give clues as to how future anti-osteoarthritic drugs should be designed.
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Coˆte de Nacre, 14032 Caen Cedex, France.OSTEOARTHRITIS (OA) is a degenerative disease that
a#ects several joints and causes severe articular
cartilage breakdown which may even lead to pro-
found alterations of the underlying subchondral
bone [1]. It is well documented that the process
involves excessive production of metalloproteases
(MMPs), such as collagenase and stromelysin,
capable of degrading the cartilage matrix. Expres-
sion of these enzymes by the resident chondrocytes
is induced by inflammatory cytokines, particularly
interleukin-1 (IL-1) and, to some extent tumor
necrosis factor-Æ (TNF-Æ) [2, 3]. Although the evo-255lution of the destructive process remains irrevers-
ible so far, evidences have been reported that the
cartilage may display anabolic signs in the early
stages of OA, suggesting that the primary lesions
can trigger the chondrocytes to proliferate and
produce an excess of matrix macromolecules,
including collagens and aggrecans [4–6]. This
anabolic reaction has been interpreted as an
attempt of repair, yet it is not clear whether the
newly synthesized matrix displays similar charac-
teristics to the normal pre-existing cartilage. Both
in-vitro and in-vivo data support the hypothesis
that the process is probably under the control of a
growth factors network, of which the nature and
functional mechanisms are practically unknown to
date. However, among the various growth factors
which have been found in the joint space and/or
in the cartilage, transforming growth factor-â
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crucial role in the repair potentialities of carti-
lage, in view of its known stimulating e#ects on
matrix synthesis which have been reported for
various tissues and experimental models [7, 8].
Indeed, TGF-â is present in the cartilage matrix
and is expressed by both chondrocytes and osteo-
blasts [9–11]. In vitro, it can enhance the expres-
sion of collagen type II and aggrecan by isolated
chondrocytes as well as cartilage explants [12–14].
Furthermore, its injection in mice joints leads to
increased proteoglycan synthesis in the articular
cartilage [15, 16]. Taking into account that the
erosion of cartilage is the prominent feature of OA,
design of future strategies in the therapeutic treat-
ment of the disease have so far essentially aimed
at finding new ways to block the biologic activities
of IL-1 in the joint tissues, for example by
taking advantage of the IL-1 receptor antagonist
(IL-1RA). However, an additional approach for
control of OA would tend to stimulate the chondro-
cyte repair capacity, in order to compensate the
cytokine-induced erosion of cartilage. Since TGF-â
has been shown to antagonize the deleterious
e#ects of IL-1, it is reasonable to think that stimu-
lation of the TGF-â system in articular chondro-
cytes might be of great benefit to maintain their
repair capacity in the OA process.
Therefore, drugs which could enhance the
expression of growth factors implicated in the
repair of articular cartilage may provide therapeu-
tic approaches in the treatment of the disease.
Diacerein (4,5-diacetoxy-9,10-dihydro-9,10-dioxo-2-
anthracenecarboxylic acid), unlike common non-
steroidal anti-inflammatory drugs, exerts its action
through mechanisms which are not well under-
stood but are probably not linked to the inhibition
of prostaglandin synthesis [17, 18]. Diacerein has
shown anti-OA e#ects in experimental animal
models [19–21] and is currently used in the treat-
ment of OA patients, with beneficial improvements
of the clinical symtoms [22, 23]. The drug is mar-
keted in France by Negma laboratories under the
name ART> 50 and is presently evaluated as a
disease-modifying OA drug (DMOAD) in a 3-year,
randomized, double-blind, placebo-control clinical
study of 500 patients with OA of the hip
(ECHODIAH study)[24].
In vitro, diacerein has been shown to inhibit
collagenase production by cultured rabbit articu-
lar chondrocytes and partially reverse IL-1-
induced inhibition of proteoglycan synthesis
[25, 26]. The drug, and its active metabolite rhein,
have been reported to inhibit superoxide release
from human neutrophils [27] and to reduce the
phagocytic ability of mouse peritoneal macro-phages [28]. All together, these data suggest that
diacerein could interfere with the cytokines/
growth factors network which plays a key role in
the imbalance of cartilage metabolism during the
OA process and may provide a rationale for the
chondroprotective e#ects of the drug. To get fur-
ther insights into the cellular mechanisms under-
lying this anti-OA action, we studied in-vitro
e#ects of diacerein on the expression of TGF-â1,
â2, â3 and their receptors I and II in cultures of
bovine articular chondrocytes, in the presence and
absence of IL-1.Materials and methodsCULTURE AND TREATMENT OF ARTICULAR CHONDROCYTES
Chondrocytes were freshly isolated from calf
cartilage as previously described [29] and used in
primary cultures to minimize phenotype modula-
tion. The cells were plated at 3–5#104/cm2 in
either 175-cm2 flasks (RNA extraction) or six-well
plates (9.6 cm2) (TGF-â protein measurement). For
transfection, the cultures were prepared at a seed-
ing density of 15#103/cm2 in 100-mm plates and
used at approximately 75% of confluency. The
cultures were incubated in Dulbecco’s modified
Eagle’s medium (DMEM) (high glucose) contain-
ing 10% fetal calf serum (FCS) and antibiotics at
37)C in an atmosphere of 5% CO2, 95% air, until
the confluence was reached (except for transfec-
tion experiments). They were then incubated with
diacerein (generally 10"5 M) provided by Negma
Laboratories, (Toussus-le-Noble, Paris), and
10 ng/ml IL-1â (a generous gift from Dr Soichiro
Sato, Shizuoka, Japan) for the indicated times.
Since diacerein was dissolved in dimethylsulfoxide
(DMSO), controls containing the same concen-
tration of DMSO (1/1000 v/v) were included in all
the experiments. These later were repeated at least
twice and data from a representative set are
shown.RNA EXTRACTION
Total RNA was isolated by the acidified guanid-
ium isothiocyanate method, using a commercial
kit (RNAXel from Eurobio, France). The RNA
concentrations were determined by measuring the
OD260. The OD260/OD280 ratios were greater than
1.8. Integrity of RNA samples was controlled by
running a 1% agarose gel electrophoresis in the
presence of ethidium bromide. In case of contami-
nating genomic DNA, an additional precipitation
with 6M LiCl was performed to obtain pure RNA
samples.
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Ten micrograms of denatured RNA samples were
run on a 1% agarose formaldehyde gel. The RNA
was then transferred by capillary action to a nylon
membrane (Pall Biodyne, Gelman Sciences) and
immobilized by ultraviolet radiation (Bioblock UV
Crosslinker, France). Two di#erent probes were
used to assess mRNA levels for TGF-â1 and
â-actin: (a) a 336 base pair (bp) cDNA probe for
TGF-â1 was generated by RT-PCR using the
primers indicated below, (b) a 548 bp probe of
â-actin generated by reverse transciptase-
polymerase chain reaction (RT-PCR) with the
specific primers listed below. The cDNA probes
were radiolabeled using the Random Primers
Labelling Kit (Gibco BRL, France) and [32P]-dCTP
(Amersham, France) as the radiolabel. Each probe
was hybridized separately at 55)C and washed
twice for 20 min at room temperature and once at
55)C with 0.1% SDS-containing 2#SSC bu#er.
Signals were detected by contact film autoradiog-
raphy using Kodak XAR5 film with intensifying
screens. The relative optical density of the autora-
diographic signals was normalized versus â-actin
levels using two-dimensional laser scanning densi-
tometry and ImageQuaNt software (Molecular
Dynamics, France).RT-PCR ANALYSIS
One-microgram samples of total RNA were
reverse transcribed into cDNA in the presence of
100 pM antisense primer, 10 units of RNAsin
(Promega), 10 mM dithiothreitol, 0.5 mM of each
desoxynucleotide triphosphate (dNTPs) (Life
Technologies), first strand bu#er 5X and 60 units of
Moloney murine leukemia virus-reverse tran-
scriptase (Life Technologies). The reaction was
performed at 42)C for 1 h. Amplification of gener-
ated cDNA was performed in an Omni E Hybaid
thermocycler using the Life Technologies PCR kit,
in the presence of both sense and antisense
primers: TGF-â1, sense 5*-GCC CTG GAC ACC
AAC TAT TGC-3*/antisense 5*-GCT GCA CTT GCA
GGA GGG CAC-3* [30]; TGF-â2, sense 5*-GCT TTG
GAT GCG GCC TAT TGC-3*/antisense 5*-GCT
GCA TTT GCA AGA CTT TAC-3* [30]; TGF-â3,
sense 5*-GCT TTG GAC ACC AAT TAC TGC-3*/
antisense 5*-GCT ACA TTT ACA AGA CTT CAC-3*
[30]; TâR-I, sense 5*-ACG TTC GTG GTT CCG
TGA G-3*/antisense 5*-TAA GTC TGC AAT ACA
GCA AGT TCC ATT CTT-3* [31]; TâR-II, sense
5*-CGC TTT GCT GAG GTC TAT AAG GCC-3*/
antisense 5*-GAT ATT GGA GCT CTT GAG GTC
CCT -3* [32]; â-Actin, sense 5*-GTG GGG CGC CCCAGG CAC CA-3*/antisense 5*-CTC CTT AAT GTC
ACG CAC GAT TTC-3* [30]. Thirty-five cycles were
done using the following conditions: 95)C for
30 sec, 55)C for 30 sec and 72)C for 1 min. Then, an
additional step at 72)C for 10 min was included.
The number of cycles was selected in the exponen-
tial phase of the amplification curve previously
established [33]. Transcripts were analyzed in 2%
agarose gel electrophoresis and visualized by
ethidium bromide staining. The amplification reac-
tions yielded expected transcript sizes (TGF-â1:
336 bp, TGF-â2: 336 bp, TGF-â3: 336 bp, TâR-I:
339 bp, TâR-II: 454 bp, â-actin: 548 bp). Identity of
the PCR products was also confirmed by restric-
tion endonuclease digestion and by southern-blot,
using respective human probes which correspond,
for TâR I and RII, to full-length cDNAs and for
TGF-â1, TGF-â2, â-actin to fragments generated by
RT-PCR. After photography of the gels with 665
Polaroid film, the intensity of corresponding bands
was quantified by densitometric scanning per-
formed with ImageQuaNt software (Molecular
Dynamics) and normalized to â-actin mRNA levels.MEASUREMENT OF SECRETED MATURE TGF-â BY GROWTH
INHIBITION OF CCL-64 MINK LUNG CELLS
To measure the amount of active TGF-â in the
media conditioned by control or diacerein-treated
cells, confluent monolayer cells in six-well culture
plates were incubated for 24 h in the 10% FCS-
containing medium, with or without 10"5 M
diacerein. The cells were washed three times with
a serum-free medium supplemented with 200 ìg/ml
BSA (serum bovine albumin) for 5, 30 and 60 min,
and incubated in 1 ml of the serum-free medium for
an additional 6 h period. The conditioned medium
was then collected in siliconized microcentrifuge
tubes, centrifuged and kept at "70)C until use.
Before the assay, 0.5 ml of cell culture supernate
was acidified by adding 0.1 ml of 1 N HCl, incu-
bated for 10 min at room temperature and neutral-
ized with 0.1 ml of 1.2 N NaOH/0.5 M HEPES.
CCL-64 cell cultures in proliferative state were
prepared as described previously [34], by seeding
2#104 cells/well in 24-well plates and grown in
10% FCS-medium. Twenty-four hours later, they
were washed with serum-free medium and incu-
bated for 24 h with 0.5 ml of chondrocyte condi-
tioned media or increasing concentrations of
exogenous TGF-â1 to establish a reference curve
of growth inhibition. The cultures were pulsed
with 0.5 µCi/ml of [3H]thymidine (40–60 Ci/mmole,
NEN., France) over the last 4-hour period of
incubation. Cells were fixed with cold 5% (v/v)
trichloracetic acid, rinsed with the same solution
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scintillation liquid.
To check the specificity of the assay, CCL-64
cells were prepared as described above. Twenty-
four hours after seeding, they were preincubated
for 30 min at 37)C with increasing concentrations
of TGF-â1, â2, and â3 antibodies (R & D Systems).
Thereafter, exogenous TGF-â1, â2, and â3 (0.5 ìg/
ml) were added for 24 h and the cells were
pulsed with tritiated thymidine as described for
conditioned media.CELL TRANSFECTION AND LUCIFERASE ACTIVITY ASSAY
For transient transfections, cells were plated in
100-mm Petri dishes and grown to 70–80% of con-
fluence. Cells were then cotransfected by the
calcium phosphate coprecipitation method [35],
with 9 ìg of the appropriate plasmids and 3 ìg
of pSV40-â Gal (Promega), a â galactosidase
expression vector used as an internal control to
normalize for transfection e$ciency. After 24 h,
the medium was changed to medium containing
DMSO (1/1000) in the absence or presence of
10"5 M diacerein. Cells were harvested 48 h after
DNA addition and extracts were assayed for
luciferase activity. Briefly, the dishes were washed
twice with PBS, and the cells were lysed with
300 ìl of lysis bu#er (0.45 mM Tris-HCl, pH 7.5).
The lysates were submitted to three cycles of
freeze–thaw. After centrifugation, luminescence of
a 50-ìl aliquot of lysate from each dish was
measured in a luminometer (Berthold Lumat 9501)
for 20 s after the addition of luciferin (Luciferase
Assay System, Promega). To normalize the
luciferase activity, protein concentration and â
galactosidase activity were determined. Protein
concentration of 4 ìl cell lysates from each dish
was measured by the Bradford’s method [36].
Cell lysates were assayed for â galactosidase
activity using resofurin â-D galactopyranoside as
substrates and the OD measured.572CONSTRUCTION OF PLASMIDS
The TGF-â1 promoter constructs were generated
using plasmid phTG2 [37] kindly provided by
Dr S. J. Kim (Laboratory of Chemoprevention,
NIH/NCI; Bethesda). phTG2 was digested by vari-
ous restriction endonucleases and the DNA frag-
ments were then cloned into a promoterless
luciferase reporter plasmid, basic pGL2 (Promega).
Constructs containing sequences from "1132 to
+11, "732 to +11, were obtained by digestion of
phTG2 respectively with HindIII and Xba I. Afterfilling in the ends with Klenow fragments, these
DNA sequences were digested with Kpn1 and
cloned into a SmaI-Kpn1 site of the plasmid basic
pGL2. The "454/+11 construct was prepared as a
HincII-Kpn1 restriction fragment from phTG2 and
was cloned into a SmaI-Kpn1 site of the plasmid
basic pGL2.ResultsEFFECT OF DIACEREIN ON mRNA EXPRESSION OF TGF-â1, â2
AND â3
We first determined the e#ect of diacerein on the
steady-state level of TGF-â1 mRNA, using a 24 h
treatment period and a concentration of 10"5 M,
which has been previously shown to be within the
range of pharmacological blood levels measured in
patient treatment [38] and also capable of acting in
similar experimental conditions on the expression
of other genes, such as collagenase, by cultured
chondrocytes [25]. Interleukin-1 was added alone
or in combination with diacerein in order to esti-
mate the influence of this cytokine which is known
to play a crucial role on chondrocytes in the OA
process.
As illustrated in Fig. 1, diacerein induced a
dramatic increase in TGF-â1 mRNA level. IL-1â
did not significantly a#ect the message for TGF-â1.
Interestingly, in the presence of IL-1, diacerein
was still capable of enhancing TGF-â1 expression,
but to a lesser extent. Additional experiments were
then carried out to evaluate the e#ects of diacerein
on the message levels for the other isoforms of
TGF-â, TGF-â2 and TGF-â3. In that case, we pref-
erentially used RT-PCR instead of Northern-blot
technique as better detection was observed with
the former method, probably because TGF-â2 and
TGF-â3 were much less expressed by the chondro-
cytes than was TGF-â1. As represented in Fig. 2,
TGF-â2 mRNA level was also increased by diac-
erein. However, upon stimulation with IL-1â, the
e#ect was no more visible, the intensity of the
band being rather similar to that of IL-1 alone.
Under these experimental conditions, the level of
TGF-â3 message remained unchanged.EFFECT OF DIACEREIN ON THE RELEASE OF MATURE TGF-â
To determine whether the increase of mRNA
levels observed for TGF-â1 and TGF-â2 was
accompanied by an augmentation of the protein
synthesis, we assayed the production of total
mature TGF-â released into the culture medium
under similar conditions. After activation of the
supernatants by acidification, the samples were
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thelial cells in their exponential growth phase. As
can be seen on Fig. 3, incubation of chondrocytes
with 10"5 M diacerein for 24 h resulted in a six-
fold increase of TGF-â production, demonstrating
that transcriptional e#ect of the drug is associated
with a corresponding translational activity.FIG. 1. E#ect of diacerein and IL-1 on expression of
TGF-â1. Bovine articular chondrocytes were plated at
6#106 cells per 175-cm2 flasks in DMEM containing
10% FCS. The media were changed every two days until
the cultures reached confluency. At that time, they were
treated for 24 h with 10"5 M of diacerein (DAR) and
10 ng/ml of IL-1 alone or in combination. Thereafter,
total RNA was extracted and 10 ìg were run on 1%
agarose gel electrophoresis and transferred to nylon
membrane. The filter was hybridized successively with
TGF-â1 and â-actin probes as described under ‘Materials
and methods’.FIG. 2. E#ect of diacerein and IL-1 on expression of
TGF-â2 and â3. Articular chondrocytes were cultured as
in Fig. 1, and 1 ìg of total RNA was reverse trancribed
into cDNA by using specific antisens primer for TGF-â2,
â3 and â-actin. Thirty-five PCR cycles were performed
under conditions described in ‘Materials and methods’
as deduced from preliminary amplification curves. Prod-
ucts were analysed in 2% agarose gel electrophoresis in
the presence of ethidium bromide and photographied
under UV light.EFFECT OF DIACEREIN ON CELLULAR EXPRESSION DIRECTED
BY THE 5* FLANKING REGION OF THE TGF-â1 GENE
In view of the preceding results which suggested
that diacerein was able to stimulate the transcrip-
tional activity of the TGF-â1 gene promoter, we
carried out transient transfections of the chondro-
cytes with a series of deleted fragments of the
5*-promoter region of the human TGF-â1 gene
fused to the luciferase reporter gene in order to
delineate the cis-sequences that could mediate the
e#ect of the compound. The constructs were trans-
fected into the cell cultures which were then
treated for 24 h with 10"5 M diacerehin. The
expression of the luciferase activity was measured
for each plasmid. As shown in Fig. 4, the largest
construct used ("1132 to +11) induced a 13-fold
increase of activity compared to the control. Theother sequences corresponding to the more down-
stream region ("1038 to +11) did not produce
significant change in the luciferase expression. To
determine if the metabolite of diacerein, rhein, was
also capable of stimulating the transcriptional
activity of the TGF-â1 promoter, two of the con-
structs ("1132 and "454 bp) were used and the
transfected cultures exposed directly to rhein. A
three-fold increase of activity was observed with
rhein on the largest construct, indicating that
rhein exerts the same e#ect but to a lesser extent
(Fig. 4, insert). These data suggest that the DNA
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ing e#ect on TGF-â1 gene expression are located
between "1132 and "1038 bp. Further analysis is
presently undertaken to more precisely delineate
this regulatory region.EFFECT OF DIACEREIN ON THE EXPRESSION OF TGF-â
RECEPTORS
As the biological activity of TGF-â is mediated
through its binding to cell membrane receptors, we
explored the e#ect of diacerein on the expression
of TGF-â receptors by measuring the correspond-
ing mRNA levels. Figure 5 shows the results of a
typical RT-PCR analysis where the data were
obtained from the exponential phase of amplifica-
tion and normalized to the levels of â-actin deter-
mined in parallel. The message for TâR-I was
increased by 10"4 M diacerein at 12 h. IL-1 has a
tendency to reduce the level of TâR-I mRNA, an
e#ect which seems to be reinforced in the presence
of diacerein. At 24 h, no significant change was
observed for TâR-I message except that IL-1
enhanced the values when added alone to the
cultures. TâR-II mRNA levels remained una#ected
by the treatments at 12 h. In contrast, all the
agents exerted an inhibitory e#ect at 48 h. In
particular, IL-1 was shown to constantly decrease
the expression level of TâR-II at this time of
exposure.FIG. 3. E#ect of diacerein on expression of TGF-â pro-
tein. The measurement of active TGF-â proteins was
performed after a 24-h treatment with 10"5 M diacerein,
three washes with serum free medium supplemented
with BSA and a final 6 h-incubation with 1 ml of the
same medium (see ‘Materials and methods’). The remain-
ing supernatant was activated by acidic treatment and
total TGF-â activity was determined by the CCL64 assay.
A dose-response reference curve has been established
with exogenous TGF-â1. Values are means&s.e.m. (N=3)
and significance of the di#erence between treated and
control cultures was established by Student’s t-test
(*Pƒ0.05). A: Results were obtained as percentage of
tritiated thymidine incorporation inhibition and
expressed as amount of produced TGF-â. B: Parallel
cultures were prepared and preincubated for 30 min with
TGF-â1 (anti-â1), TGF-â2 (anti-â2) and TGF-â3 (anti-â3)
respective antibodies at increasing concentrations.
Thereafter, TGF-â1, â2 and â3 were added at final
concentration of 0.5 ng/ml and the proliferation was
measured by tritiated thymidine incorporation as above.Discussion
The potential role of TGF-âs and their related
peptides BMP (bone morphogenetic peptides) in
the control of both cartilage homeostasis and
repair has been extensively explored over the last
few years. Several in-vitro studies have demon-
strated that this growth factor can counteract the
e#ects of interleukin-1 on the catabolism as well
as on the synthesis of chondrocyte matrix com-
ponents (reviewed in [8]). Furthermore, it has been
shown that intra-articular injections of TGF-â
into mice joints induced an increase of cartilage
proteoglycan synthesis and even promoted forma-
tion of osteophytes if the dose and number of
injections are too high [15, 16]. The recent finding
that the expression of TGF-â receptor II is dramati-
cally reduced to barely detectable levels in the
fibrillated cartilage of the rabbit OA model [39]
and that transgenic mice expressing a truncated,
kinase-defective, TGF-â type II receptor develop a
degenerative joint disease resembling human OA
[40] places greater emphasis on the role of this
factor in this disease. From these data, it seems
probable that the OA process is accompanied by a
progressive reduction of chondrocyte responsive-
ness to TGF-â and therefore an incapacity to
counter the IL-1-induced degradation. In this con-
text, any agent that could stimulate the expression
of TGF-âs or the signaling pathway of these factors
in cartilage may have some interest for OA treat-
ment and provides a valuable contribution to the
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chondrocytes were plated at a density of 1.2#106 in 55 cm2 Petri dishes and grown in DMEM containing 10% FCS to
70–80% of confluency. Cells were then cotransfected with 9 ìg of the di#erent TGF-â1 promoter constructs and 3 ìg of
pSV40-â Gal. 24 h after the transfection, the cultures were washed and treated or not with diacerein 10"5 M (and rhein
10"5 M, see insert). 48 h after DNA addition, the cells were harvested and luciferase activity was determined as
relative light units (RLU) normalized to â galactosidase activity and protein concentration. Results are expressed as
diacerein/rhein-induced increase of luciferase activity. Values are means&s.e.m. (N=3).development of new therapeutic strategies in this
field. In the present study, we have demonstrated
that diacerein and its active metabolite rhein can,
at therapeutic concentrations, increase the expres-
sion of TGF-â1 and TGF-â2. This e#ect was consist-
ent throughout the study but was shown for
concentration thresholds and exposure times
slightly variable depending on the chondrocyte
strains. This variation is probably related to the
fact that, depending on the age of animals from
which the cells are obtained, the responsiveness of
chondrocytes may be di#erent. Moreover, the rate
of diacerein metabolization into rhein, the active
derivative, is likely to depend also on the cell
strain and therefore may vary between exper-
iments. However, the drug concentrations used
here and shown to be e$cient on TGF-â1 and â2
expression are well within the therapeutic range of
OA patients treated with diacerein [38].Interestingly, we demonstrate also that diac-
erein was still capable to exert its enhancing e#ect
on TGF-â1 gene expression, although to a lesser
extent, in the presence of IL-1, an experimental
condition which mimics in some way the situation
encountered by chondrocytes in OA cartilage. It
must be remembered that we previously showed an
inhibitory e#ect of diacerein on the IL-1-induced
collagenase synthesis by chondrocytes [25, 26].
Thus, the present finding is consistent with a poss-
ible mechanism linking the action exerted by the
drug on both cytokine specific e#ects. By stimulat-
ing the expression of TGF-â1 and -â2, diacerein can
first trigger the feedback loop of auto-induction
of TGF-â1 [41], amplifying its sphere of activity,
and secondly may counteract the IL-1-induced
degradative process [8].
It is of note that in our study, the stimulating
e#ect of diacerein was generally greater on the
262 Felisaz et al.: Diacerein stimulates TGF-â expression of chondrocytesFIG. 5. E#ect of diacerein and IL-1 on the expression of TGF-â receptors I and II. Bovine articular chondrocytes were
cultured as described above in 175 cm2 flasks treated at confluency with 10"5 M diacerein and 10 ng/ml of IL-1 alone
or in combination. Total RNA was extracted after 12 and 24 h of incubation. 1 ìg were used for reverse transcription
of both TGF-â receptors type I and type II and â-actin. PCR reactions were carried out for increasing numbers of cycles
(25, 30 and 35) in order to check the linearity of amplification. Products of the amplifications were run on 2% agarose
gel electrophoresis and signals were scanned for further analysis with ImageQuaNT software (Molecular Dynamics).
Results are expressed as histograms of TâR I or TâR II relative expression versus that of â-actin.expression of TGF-â1 than of TGF-â2. This finding
is most important, as several evidences have been
accumulated that expression of TGF-â1 is di#er-
ently regulated than the two other isoforms
[42, 43]. Characterization of the promoters of
human TGF-â1, 2 and 3 has revealed significant
di#erences in the regulatory features of these
three promoters [37]. The TGF-â1 promoter con-
tains no TATA box but instead a cluster of Sp1
sites just upstream from the transcriptional start
sites. The three Ap-1 sites, which mediate auto-
induction of TGF-â1 [41], seem to be critically
important in the regulation of TGF-â1 expression
in a variety of physiological and pathological con-
ditions and could explain perhaps that TGF-â1
expression appears to be more sensitive tocytokines/growth factors control than those of
TGF-â2 and â3. Since only the TGF-â1 gene has
been found to contain functionally active AP-1
binding sites, it has been suggested that many of
the increases in TGF-â1 transcription observed in
transformed cells, in wound healing, and in
chronic inflammatory diseases might be mediated
through activation of the AP-1 sites by Jun and
Fos, either directly or indirectly.
Transfection experiments presented here sug-
gest that the stimulating e#ect of diacerein on
TGF-â1 expression could be mediated through
positive regulatory sequences located between
"1132 and "1038 bp of the 5*-upstream region of
the promoter. This region is therefore di#erent
from the zone "453/"333 bp previously identified
Osteoarthritis and Cartilage Vol. 7 No. 3 263as the zone responsible for auto-induction and
which contains the major consensus transcription
factor binding site, AP-1 [37]. However, the
"1132/"1038 region shown here to be implicated
in the e#ect of diacerein corresponds precisely to
the sequence which contains an enhancer-like
zone capable of compensating the more down-
stream negative regulatory region "731/"443
[37]. This region, which has not been yet investi-
gated, does not contain distinct recognizable tran-
scriptional factor binding sites but GC-rich
sequences are present, suggesting that they could
be putative binding sites for zinc-finger proteins.
We are currently attempting to further delineate
this sequence and determine which transcription
factors might be implicated at this level.
Under the present experimental conditions, no
clear and significant e#ects of diacerein on the
expression of both TGF-â receptors I and II were
observed, and there is a doubt that the slight
variations we found could have some influence on
the factor binding potentialities of the chondro-
cyte and the subsequent signaling pathways. In
contrast, we found a reproducible negative e#ect
of IL-1 on the expression of the TGF-â receptor II
which is known as the crucial part of the cell
binding system. This data is consistent with the
fact that chondrocytes may become less sensitive
to TGF-â in the OA process where excess of IL-1 is
known to be a major characteristic of the a#ected
joints.
To date, very few drugs have proven capable of
stimulating TGF-â expression. Taken into the con-
text of the recent findings supporting the role of
TGF-â in cartilage repair potentialities [39, 40],
this study may explain some of the mechanisms
through which diacerein exerts a therapeutic
e#ect in OA. Together with its already reported
inhibitory e#ect on IL-1-induced collagenase
expression, its capability to stimulate TGF-â
expression points to the potential interest of this
drug to the repair of cartilage.References
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